Dashboard
1
Poor Management Efficiency with a low ROCE of 1.11%
- The company has been able to generate a Return on Capital Employed (avg) of 1.11% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 4.67% and Operating profit at -21.40% over the last 5 years
4
The company has declared Negative results for the last 3 consecutive quarters
5
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,608 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.73
-7.16%
3.42
Revenue and Profits:
Net Sales:
190 Million
(Quarterly Results - Mar 2026)
Net Profit:
-9 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.04%
0%
-11.04%
6 Months
-2.05%
0%
-2.05%
1 Year
-3.38%
0%
-3.38%
2 Years
0.88%
0%
0.88%
3 Years
0%
0%
0.0%
4 Years
-7.74%
0%
-7.74%
5 Years
-26.76%
0%
-26.76%
Beijing Bohui Innovation Biotechnology Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.67%
EBIT Growth (5y)
-21.40%
EBIT to Interest (avg)
-0.09
Debt to EBITDA (avg)
8.80
Net Debt to Equity (avg)
0.77
Sales to Capital Employed (avg)
0.39
Tax Ratio
24.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.11%
ROE (avg)
0.69%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.35
EV to EBIT
-264.41
EV to EBITDA
59.58
EV to Capital Employed
2.39
EV to Sales
7.29
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.91%
ROE (Latest)
-5.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
189.90
195.80
-3.01%
Operating Profit (PBDIT) excl Other Income
1.40
-62.80
102.23%
Interest
8.70
11.60
-25.00%
Exceptional Items
0.00
-7.70
100.00%
Consolidate Net Profit
-8.80
-110.50
92.04%
Operating Profit Margin (Excl OI)
7.60%
-468.40%
47.60%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -3.01% vs -12.90% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 92.04% vs -256.45% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
819.50
848.00
-3.36%
Operating Profit (PBDIT) excl Other Income
69.30
172.90
-59.92%
Interest
34.80
29.80
16.78%
Exceptional Items
-88.30
-11.70
-654.70%
Consolidate Net Profit
-172.00
8.70
-2,077.01%
Operating Profit Margin (Excl OI)
-54.30%
67.50%
-12.18%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -3.36% vs -18.53% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -2,077.01% vs -44.59% in Dec 2024
About Beijing Bohui Innovation Biotechnology Group Co., Ltd. 
Beijing Bohui Innovation Biotechnology Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






